🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against superbug strains of the pathogen, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are on the rise globally, with data suggesting over 82 million infections per year. Notably increased rates are reported in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are deeply concerned about the surge in treatment-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to develop it.

“This approval signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Worldwide Availability

As per data detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The study included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have expressed optimism. The availability of a easy-to-administer therapy of this kind is seen as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.